SCHEMBL869287

SCHEMBL869287

CCc1c(O)c(=O)ccn1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.62
KDM6A O15550 1/20 0.62
KDM4A O75164 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
KDM5C P41229 1/20 0.62
KDM2B Q8NHM5 1/20 0.62
DOHH Q9BU89 1/20 0.62
KDM2A Q9Y2K7 1/20 0.62
TP53 P04637 1/20 0.41
CYP2D6 P10635 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
COMT P21964 2/20 0.41
MMP1 P03956 1/20 0.38
MMP7 P09237 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
APP P05067 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10404502 0.98 KDM4E (0.60) KDM4EKDM6AKDM4ACYP2C9CYP2C19
Deferiprone SCHEMBL6400926 0.93 KDM4E (0.76) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL6995058 0.84 KDM4E (0.62) KDM4EKDM6AKDM4ACYP2C9CYP2C19
Hydrochloric Acid SCHEMBL6997040 0.82 KDM4E (0.60) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL18117860 0.82 KDM4E (0.60) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL8615538 0.82 KDM4E (0.60) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL4546216 0.81 KDM4E (0.58) KDM4EKDM6AKDM4ACYP2C9CYP2C19
Deferiprone SCHEMBL7224598 0.80 KDM4E (0.67) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL5515462 0.79 KDM4E (0.47) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL9700190 0.79 KDM4E (0.56) KDM4EKDM6AKDM4ACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567156-B1 HYDROXYPYRIDINONES FOR THE LOCAL TREATMENT OF SKIN MICROCIRCULATORY DISORDERS RELIVIA SRL (IT) 2009-08-26 EP claimed
US-7160482-B2 Composition comprising an oxidizing and complexing compound IMEC VZW (BE) 2007-01-09 US claimed
US-20050009207-A1 Composition comprising an oxidizing and complexing compound VERSUM MATERIALS US, LLC 2005-01-13 US claimed
US-11654137-B2 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same GEORGIA TECH RESEARCH CORPORATION (US) 2023-05-23 US disclosed
US-9938240-B2 Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX INC. (CA) 2018-04-10 US disclosed
EP-2684222-B1 ALUMINIUM OXIDE PASTES AND METHOD FOR THE USE THEREOF MERCK PATENT GMBH (DE) 2018-03-28 EP disclosed
US-20170247329-A1 \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ APOTEX TECHNOLOGIES INC. (CA) 2017-08-31 US disclosed
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones THE BANK OF NOVA SCOTIA (CA) 2017-03-30 US disclosed
CN-103493220-B Alumina paste and method of use thereof 默克专利股份有限公司 2017-03-01 CN disclosed
US-9580610-B2 Aluminium oxide pastes and process for the use thereof MERCK PATENT GMBH (DE) 2017-02-28 US disclosed
CN-103429681-B Printable alumina ink formulations 默克专利股份有限公司 2017-02-15 CN disclosed
EP-0829104-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1998-03-18 EP disclosed
EP-0808103-A1 PROTEIN HYDROXYLATION INHIBITORS FOR FIBROPROLIFERATIVE DISORDERS CORNELL RESEARCH FOUNDATION, INC. (US) 1997-11-26 EP disclosed
EP-0729648-A4 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LTD (AU) 1997-01-02 EP disclosed
WO-1996035239-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-11-07 WO disclosed
EP-0729648-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-09-04 EP disclosed
WO-1996022021-A1 PROTEIN HYDROXYLATION INHIBITORS FOR FIBROPROLIFERATIVE DISORDERS CORNELL RESEARCH FOUNDATION, INC. (US) 1996-07-25 WO disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 WO disclosed
WO-1989009211-A1 PROCESS FOR PRODUCING PYRID-4-ONES THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) 1989-10-05 WO disclosed
EP-0335745-A1 Process for producing pyrid-4-ones THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) 1989-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11654137-B2 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same KDM1B, KDM3A, KDM1A KDM4E 10/4885KDM6A 18/4885KDM4A 5/4885
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones FH, FECH, FPGS KDM4E 2785/4885KDM6A 3395/4885KDM4A 3662/4885
US-20170247329-A1 \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ FH, FECH, FPGS KDM4E 2376/4885KDM6A 3191/4885KDM4A 3448/4885
US-20050009207-A1 Composition comprising an oxidizing and complexing compound C5, SCO2, NOX4 KDM4E 2769/4885KDM6A 2283/4885KDM4A 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.